Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lali Medina-Kauwe
Cedars Sinai Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
EOS Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
EOS Biosciences is interested in developing the technology being used in this Study as a product for eventual use in the clinic. Although the funding will support basic biology and mechanistic studies surrounding this same technology and not necessarily product development, development of the basic biology and mechanistic studies must influence the expected product for eventual use.
Protein-DNA Drug Carriers for Targeting Drug-Resistant Tumors
The majority of tumor-targeted therapies currently used in the clinic are aimed at blocking signal transduction that normally supports cell growth and survival, but the majority of cases do not respond to signal-blocking therapies, while the majority of those who do initially respond develop resistance within one year. As these resistant tumors acquire mechanisms that sustain signaling in the face of targeted treatment, there is a need for alternative strategies that are not reliant on signal-modulation. This study addresses that need by introducing a nanobiologic with the capacity to not only specifically home to such resistant tumors, but also deliver toxic molecules through tumor-targeted penetration while circumventing the need to modulate signaling.
Filed on September 18, 2015.
Tell us what you know about Lali Medina-Kauwe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Lali Medina-Kauwe filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lali Medina-Kauwe | Cedars Sinai Medical Center | Conflict of Interest | EOS Biosciences | $20,000 - $39,999 |
| Lali Medina-Kauwe | Cedars Sinai Medical Center | Conflict of Interest | EOS Biosciences | $0 - $4,999 |
| Lali Medina-Kauwe | Cedars Sinai Medical Center | Conflict of Interest | EOS Biosciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.